Bluebird Bio Stock Is in Free Fall Weeks After Landmark FDA Approval. Here’s Why.

Two weeks ago,

bluebird bio secured Food and Drug Administration

approval for its gene therapy for sickle cell disease, a significant milestone for the roughly 100,000 people in the U.S. who suffer from the condition.

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button